Institutional investors purchased a net $3.6 million shares of MACK during the quarter ended June 2014. This may signal that the smart money is gaining interest in this company as the 55.00% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
B&T CAPITAL MANAGEMENT, INC. Bought 273.1 Thousand shares of Merrimack Pharmaceuticals...